Theravance Biopharma
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $20,731 | $17,699 | $45,891 | $19,990 |
Gross Profit | 19,288 | 17,699 | 44,385 | 11,878 |
EBITDA | 839 | -5,635 | 75,158 | -1,907 |
EBIT | -604 | -6,470 | 73,652 | -2,316 |
Net Income | -5,898 | -4,933 | 61,024 | 3,615 |
Net Change In Cash | 20,731 | 17,699 | 45,891 | 19,990 |
Free Cash Flow | -8,881 | 73,279 | -6,072 | -6,508 |
Cash | 219,766 | 288,101 | 167,806 | 174,773 |
Basic Shares | 51,667 | 51,279 | 53,053 | 51,908 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $107,464 | $64,381 | $57,424 | $51,346 |
Gross Profit | 101,949 | 26,738 | 16,803 | -12,046 |
EBITDA | 137,223 | -38,453 | -51,648 | -76,084 |
EBIT | 131,708 | -42,068 | -53,649 | -79,119 |
Net Income | 105,895 | -56,418 | -55,193 | 872,132 |
Net Change In Cash | 107,464 | 64,381 | 57,424 | 51,346 |
Cost of Revenue | 208,212 | |||
Free Cash Flow | 238,499 | -11,867 | -29,485 | -187,563 |
Cash | 167,806 | 37,797 | 39,545 | 298,172 |
Basic Shares | 51,507 | 48,847 | 55,303 | 73,591 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | $0.07 |
2026-03-31 | $0.01 |
2025-12-31 | $0.05 |
2025-09-30 | $0.04 |